Stock RNXT RENOVORX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.243 USD +2.73% Intraday chart for RenovoRx, Inc. +6.24% -45.72%
Apr. 16 RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting CI
Apr. 15 RenovoRx, Inc. announced that it has received $11.136652 million in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement
AQ
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
BU
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech
AQ
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
BU
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
CI
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
BU
RenovoRx, Inc. announced that it has received $11.136652 million in funding
CI
RenovoRx Announces $11.1 Million at Market Private Placement
BU
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
AQ
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
BU
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding
CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
BU
RenovoRx Highlights Key Leadership Promotions
AQ
RenovoRx Highlights Key Leadership Promotions
BU
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024
CI
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer
CI
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer
CI
RenovoRx CEO Issues Letter to Shareholders
BU
Alliance Global Starts RenovoRx With Buy Rating, $4 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNXT Stock
  4. News RenovoRx, Inc.